Galectin Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $80 |
Gross Profit | -9 | -9 | 71 | |
EBITDA | -9,717 | -11,093 | -10,428 | -9,141 |
EBIT | -9,726 | -11,102 | -10,437 | -9,150 |
Net Income | -11,220 | -12,371 | -11,489 | -9,997 |
Net Change In Cash | 0 | 0 | 0 | 80 |
Free Cash Flow | -8,538 | -8,333 | -12,105 | -4,702 |
Cash | 27,060 | 25,598 | 23,555 | 25,660 |
Basic Shares | 62,278 | 62,233 | 61,976 | 61,852 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -33 | -32 | -41 | -36 |
EBITDA | -202 | -37,711 | -29,997 | -23,342 |
EBIT | -38,274 | -37,743 | -30,038 | -23,378 |
Net Income | -41,066 | -39,200 | -30,975 | -23,516 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | -20,338 | |||
Free Cash Flow | -32,965 | -31,056 | -24,308 | -20,601 |
Cash | 25,660 | 18,592 | 39,648 | 27,142 |
Basic Shares | 60,159 | 59,391 | 58,527 | 57,029 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.18 |
2024-06-30 | -$0.20 |
2024-03-31 | -$0.19 |
2023-12-31 | -$0.16 |
